Amgen Provides Ambitious Update On Biosimilars Business

CEO Says Company Expects To Double Biosimilar Revenues To Around $4bn By 2030

 
• By Chloe Kent

Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.

Amgen offices at Cambridge Science Park
Amgen has restated its ambitions to double the value of its biosimilars business by 2030 • Source: Alamy

More from Biosimilars

More from Products